1
|
Safi S, Sethi NJ, Korang SK, Nielsen EE, Feinberg J, Gluud C, Jakobsen JC. Beta-blockers in patients without heart failure after myocardial infarction. Cochrane Database Syst Rev 2021; 11:CD012565. [PMID: 34739733 PMCID: PMC8570410 DOI: 10.1002/14651858.cd012565.pub2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
BACKGROUND Cardiovascular disease is the number one cause of death globally. According to the World Health Organization (WHO), 7.4 million people died from ischaemic heart disease in 2012, constituting 15% of all deaths. Beta-blockers are recommended and are often used in patients with heart failure after acute myocardial infarction. However, it is currently unclear whether beta-blockers should be used in patients without heart failure after acute myocardial infarction. Previous meta-analyses on the topic have shown conflicting results. No previous systematic review using Cochrane methods has assessed the effects of beta-blockers in patients without heart failure after acute myocardial infarction. OBJECTIVES To assess the benefits and harms of beta-blockers compared with placebo or no treatment in patients without heart failure and with left ventricular ejection fraction (LVEF) greater than 40% in the non-acute phase after myocardial infarction. SEARCH METHODS We searched CENTRAL, MEDLINE, Embase, LILACS, Science Citation Index - Expanded, BIOSIS Citation Index, the WHO International Clinical Trials Registry Platform, ClinicalTrials.gov, European Medicines Agency, Food and Drug Administration, Turning Research Into Practice, Google Scholar, and SciSearch from their inception to February 2021. SELECTION CRITERIA We included all randomised clinical trials assessing effects of beta-blockers versus control (placebo or no treatment) in patients without heart failure after myocardial infarction, irrespective of publication type and status, date, and language. We excluded trials randomising participants with diagnosed heart failure at the time of randomisation. DATA COLLECTION AND ANALYSIS We followed our published protocol, with a few changes made, and methodological recommendations provided by Cochrane and Jakobsen and colleagues. Two review authors independently extracted data. Our primary outcomes were all-cause mortality, serious adverse events, and major cardiovascular events (composite of cardiovascular mortality and non-fatal myocardial reinfarction). Our secondary outcomes were quality of life, angina, cardiovascular mortality, and myocardial infarction during follow-up. We assessed all outcomes at maximum follow-up. We systematically assessed risks of bias using seven bias domains and we assessed the certainty of evidence using the GRADE approach. MAIN RESULTS We included 25 trials randomising a total of 22,423 participants (mean age 56.9 years). All trials and outcomes were at high risk of bias. In all, 24 of 25 trials included a mixed group of participants with ST-elevation myocardial infarction and non-ST myocardial infarction, and no trials provided separate results for each type of infarction. One trial included participants with only ST-elevation myocardial infarction. All trials except one included participants younger than 75 years of age. Methods used to exclude heart failure were various and were likely insufficient. A total of 21 trials used placebo, and four trials used no intervention, as the comparator. All patients received usual care; 24 of 25 trials were from the pre-reperfusion era (published from 1974 to 1999), and only one trial was from the reperfusion era (published in 2018). The certainty of evidence was moderate to low for all outcomes. Our meta-analyses show that beta-blockers compared with placebo or no intervention probably reduce the risks of all-cause mortality (risk ratio (RR) 0.81, 97.5% confidence interval (CI) 0.73 to 0.90; I² = 15%; 22,085 participants, 21 trials; moderate-certainty evidence) and myocardial reinfarction (RR 0.76, 98% CI 0.69 to 0.88; I² = 0%; 19,606 participants, 19 trials; moderate-certainty evidence). Our meta-analyses show that beta-blockers compared with placebo or no intervention may reduce the risks of major cardiovascular events (RR 0.72, 97.5% CI 0.69 to 0.84; 14,994 participants, 15 trials; low-certainty evidence) and cardiovascular mortality (RR 0.73, 98% CI 0.68 to 0.85; I² = 47%; 21,763 participants, 19 trials; low-certainty evidence). Hence, evidence seems to suggest that beta-blockers versus placebo or no treatment may result in a minimum reduction of 10% in RR for risks of all-cause mortality, major cardiovascular events, cardiovascular mortality, and myocardial infarction. However, beta-blockers compared with placebo or no intervention may not affect the risk of angina (RR 1.04, 98% CI 0.93 to 1.13; I² = 0%; 7115 participants, 5 trials; low-certainty evidence). No trials provided data on serious adverse events according to good clinical practice from the International Committee for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH-GCP), nor on quality of life. AUTHORS' CONCLUSIONS Beta-blockers probably reduce the risks of all-cause mortality and myocardial reinfarction in patients younger than 75 years of age without heart failure following acute myocardial infarction. Beta-blockers may further reduce the risks of major cardiovascular events and cardiovascular mortality compared with placebo or no intervention in patients younger than 75 years of age without heart failure following acute myocardial infarction. These effects could, however, be driven by patients with unrecognised heart failure. The effects of beta-blockers on serious adverse events, angina, and quality of life are unclear due to sparse data or no data at all. All trials and outcomes were at high risk of bias, and incomplete outcome data bias alone could account for the effect seen when major cardiovascular events, angina, and myocardial infarction are assessed. The evidence in this review is of moderate to low certainty, and the true result may depart substantially from the results presented here. Future trials should particularly focus on patients 75 years of age and older, and on assessment of serious adverse events according to ICH-GCP and quality of life. Newer randomised clinical trials at low risk of bias and at low risk of random errors are needed if the benefits and harms of beta-blockers in contemporary patients without heart failure following acute myocardial infarction are to be assessed properly. Such trials ought to be designed according to the SPIRIT statement and reported according to the CONSORT statement.
Collapse
Affiliation(s)
- Sanam Safi
- Copenhagen Trial Unit, Centre for Clinical Intervention Research, The Capital Region of Denmark, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
| | - Naqash J Sethi
- Copenhagen Trial Unit, Centre for Clinical Intervention Research, The Capital Region of Denmark, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
| | - Steven Kwasi Korang
- Copenhagen Trial Unit, Centre for Clinical Intervention Research, The Capital Region of Denmark, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
| | - Emil Eik Nielsen
- Copenhagen Trial Unit, Centre for Clinical Intervention Research, The Capital Region of Denmark, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
| | - Joshua Feinberg
- Copenhagen Trial Unit, Centre for Clinical Intervention Research, The Capital Region of Denmark, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
| | - Christian Gluud
- Copenhagen Trial Unit, Centre for Clinical Intervention Research, The Capital Region of Denmark, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
- Cochrane Hepato-Biliary Group, Copenhagen Trial Unit, Centre for Clinical Intervention Research, The Capital Region of Denmark, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
- Department of Regional Health Research, The Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark
| | - Janus C Jakobsen
- Copenhagen Trial Unit, Centre for Clinical Intervention Research, The Capital Region of Denmark, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
- Cochrane Hepato-Biliary Group, Copenhagen Trial Unit, Centre for Clinical Intervention Research, The Capital Region of Denmark, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
- Department of Regional Health Research, The Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark
| |
Collapse
|
2
|
Vedin A, Wilhelmsson C. Beta blockers after myocardial infarction--aspects on study design based on current knowledge. ACTA MEDICA SCANDINAVICA. SUPPLEMENTUM 2009; 651:227-33. [PMID: 6119877 DOI: 10.1111/j.0954-6820.1981.tb03661.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
The beta-blocker trials published so far may be subdivided into three different categories: 1) retrospective, 2) prospective non-conclusive, 3) prospective conclusive studies. The retrospective studies suffer the weaknesses of the retrospective method and may only be used as supportive evidence. There have so far been four prospective studies producing positive results, three with alprenolol and one with practolol. The studies presented support the concept that practolol and alprenolol reduce the long-term mortality due to sudden death from ischemic heart disease after myocardial infarction. All the studies have been criticized on various grounds and a list of unanswered remaining issues may be made. Acute and long-term effects of betablockade need not be the same. Our knowledge about the necessary doses and plasma levels is incomplete. All the studies published so far cover a maximum period of two years. If the study observation periods were prolonged it is likely that at some time the relative benefit becomes less. Ideal treatment should be reserved for those patients likely to derive significant benefit from it. At the present time identification of such patients is not sufficiently precise. Whether or not the beta-blockers have an antiarrhythmic effect, for instance demonstrated on chronic PVC's, this information is of little value in interpreting the proper mechanism of the beta-blockers in acute ischemia and lethal arrhythmias. In order to contribute new knowledge future studies should involve sufficiently large numbers of representative groups of patients, a stratified study design and a beta-blocker with ancillary properties different from alprenolol.
Collapse
|
3
|
Rehnqvist N, Lundman T, Sjögren A. Prognostic implications of ventricular arrhythmias registered before discharge and one year after acute myocardial infarction. ACTA MEDICA SCANDINAVICA 2009; 204:203-9. [PMID: 696421 DOI: 10.1111/j.0954-6820.1978.tb08425.x] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
The prognostic weight of ventricular ectopic beats (VEBs) was evaluated in 160 patients discharged after a CCU-treated acute myocardial infarction (AMI) and followed for two years. VEBs were registered prior to discharge by 6 hours of telemetry (3 hours during daytime including exercise and 3 hours at night) and again one year after the AMI. During the first year of follow-up, 11 patients died suddenly and 20 suffered reinfarction. Sixteen (55%) of these had shown severe VEBs, i.e. multiform, paired, R-on-T, or ventricular tachycardia, as compared to 42 (29%) of the remainder. During the second year of follow-up, eight patients suffered reinfarction and five died suddenly. The occurrence of severe VEBs prior to discharge was not of prognostic value for the second year per se but continued to carry prognostic weight for the first plus the second year. One year after the AMI the VEB incidence in 122 survivors without reinfarction increased insignificantly from 71 to 78%. VEB severity increased in 43% and decreased in 27% and the shift towards severe forms is significant. Severe VEBs one year after the AMI carry a prognostic weight for the second follow-up year, as 18% of patients with severe VEBs reinfarcted or died suddenly against 5% of those with nor or uniform VEBs only. Patients who had severe VEBs both prior to discharge and one year later did especially badly.
Collapse
|
4
|
Frishman WH, Cheng A. Secondary prevention of myocardial infarction: role of beta-adrenergic blockers and angiotensin-converting enzyme inhibitors. Am Heart J 1999; 137:S25-S34. [PMID: 10097243 DOI: 10.1016/s0002-8703(99)70393-5] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Abstract
beta-Blockers reduce cardiovascular death and reinfarction in patients with a history of myocardial infarction (MI), and angiotensin-converting enzyme (ACE) inhibitors provide an overall survival benefit in patients with signs or symptoms of left ventricular (LV) dysfunction and a history of acute MI. Despite this, these agents remain underused in clinical practice. Appropriate patient selection in standard clinical practice should be encouraged in order to achieve a mortality rate reduction comparable to that seen in clinical trials. It appears from the findings of recent studies that the greatest benefit from beta-blocker therapy is achieved in patients who are more than 60 years of age and in patients at moderate or high risk for reinfarction and death (eg, patients with LV dysfunction or arrhythmias or both). Patients with class I-IV heart failure treated with ACE inhibitors have fewer recurrent infarctions, a lower incidence of severe congestive heart failure, and a reduced incidence of total cardiovascular death and sudden cardiac death. In addition to the studies completed in patients with MI, there are ongoing studies evaluating whether or not ACE inhibitors can reduce myocardial ischemic events in patients without a prior infarction who have coronary artery disease or hypertension and preserved LV function. There is also growing evidence that concomitant therapy with a beta-blocker and an ACE inhibitor may reduce mortality rates beyond that observed with ACE inhibitors alone in survivors of MI who have LV dysfunction.
Collapse
Affiliation(s)
- W H Frishman
- Division of Cardiology, Departments of Medicine and Pharmacy, Bronx, NY, USA
| | | |
Collapse
|
5
|
Abstract
Sudden cardiac death usually occurs secondary to a ventricular tachyarrhythmia. Even under ideal circumstances only 20% of patients who have an out-of-hospital cardiac arrest survive to hospital discharge. Therefore, aggressive treatment and screening of high-risk patients are mandatory to improve survival rates. Risk stratification of high-risk patients, such as the post-myocardial infarction (MI) population, has been of limited value. Between 70% and 85% of "high-risk" post-MI patients, as defined by these screening tests, will not have a sustained ventricular tachyarrhythmia over several years of follow-up. The use of beta-blockers and possibly amiodarone may have some benefit in reducing mortality in high-risk patients after an MI. Several ongoing trials are studying the use of serial drug testing, amiodarone, and implantable cardioverter-defibrillators in reducing the incidence of sudden cardiac death in patients with potentially lethal ventricular arrhythmias. Although implantable cardioverter-defibrillators appear to be superior to antiarrhythmic drugs in reducing sudden cardiac death, total mortality may not be altered. In sustained ventricular tachyarrhythmias, sotalol and amiodarone appear to be superior to other drugs in preventing arrhythmia recurrence. Ongoing trials, such as the Antiarrhythmic Drug versus Implantable Device (AVID) trial may define the best strategy in these high-risk patients.
Collapse
Affiliation(s)
- J K Gilman
- Cardiology Service, Brooke Army Medical Center, Fort Sam Houston, Tex
| | | | | |
Collapse
|
6
|
Feuerstein G, Yue TL, Ma X, Ruffolo R. Carvedilol: A Novel Multiple Action Antihypertensive Drug that Provides Major Organ Protection. ACTA ACUST UNITED AC 1994. [DOI: 10.1111/j.1527-3466.1994.tb00285.x] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
7
|
Abstract
The evidence supporting and describing cardioprotective effects of beta-adrenergic blocker treatment is surveyed. Details of the many studies that individually and collectively document the ability of long-term and acute beta-blocker therapy to reduce overall mortality, sudden cardiovascular death, and nonfatal reinfarction in patients surviving or experiencing a myocardial infarction are described. A discussion of the mechanisms by which beta blockers probably and theoretically achieve these benefits includes the suggestion that they may reduce plaque rupture, thus indirectly inhibiting thrombosis. It is also suggested that, in the future, further cardioprotective benefits may accrue to the use of beta blockers in conjunction with thrombolysis and of beta blockers with a duration of action sustained throughout a full 24 hours.
Collapse
Affiliation(s)
- W H Frishman
- Department of Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York 10461
| |
Collapse
|
8
|
Affiliation(s)
- J K Gilman
- Electrophysiology Laboratory, University of Texas Medical School, Houston
| | | |
Collapse
|
9
|
Ruffolo RR, Boyle DA, Brooks DP, Feuerstein GZ, Venuti RP, Lukas MA, Poste G. Carvedilol: A Novel Cardiovascular Drug with Multiple Actions. ACTA ACUST UNITED AC 1992. [DOI: 10.1111/j.1527-3466.1992.tb00242.x] [Citation(s) in RCA: 45] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
10
|
Frishman WH, Lazar EJ. Reduction of mortality, sudden death and non-fatal reinfarction with beta-adrenergic blockers in survivors of acute myocardial infarction: a new hypothesis regarding the cardioprotective action of beta-adrenergic blockade. Am J Cardiol 1990; 66:66G-70G. [PMID: 1978548 DOI: 10.1016/0002-9149(90)90401-l] [Citation(s) in RCA: 49] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Beta-adrenergic blockers have been shown definitely to reduce the incidence of total mortality, cardiovascular mortality, sudden death and nonfatal reinfarction in survivors of an acute myocardial infarction. The mechanisms to explain this protective action of beta blockers have never been elucidated conclusively, and include the antiarrhythmic and myocardial oxygen demand-reducing effects of the drugs. An antithrombotic mechanism has also been suggested. However, beta blockers have relatively weak antiplatelet activity, suggesting that their antithrombotic effects may be related to prevention of coronary artery plaque rupture and the subsequent propagation of an occlusive arterial thrombus rather than direct anticoagulant action. The therapeutic ability of beta blockers to attenuate the hemodynamic consequences of catecholamine surges, may protect a vulnerable atherosclerotic plaque from fracture, thereby reducing risk of coronary thrombosis, myocardial infarction and death.
Collapse
Affiliation(s)
- W H Frishman
- Department of Medicine, Jack D. Weiler Hospital, Albert Einstein College of Medicine-Montefiore Medical Center, Bronx, New York
| | | |
Collapse
|
11
|
Kirby DA, Hottinger S, Ravid S, Lown B. Inducible monomorphic sustained ventricular tachycardia in the conscious pig. Am Heart J 1990; 119:1042-9. [PMID: 2330862 DOI: 10.1016/s0002-8703(05)80233-9] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Sustained monomorphic ventricular tachycardia (VT) is of clinical importance but has not been readily modeled in conscious animals. Eleven pigs had myocardial infarction induced by pulling snares previously placed around the left anterior descending (LAD) coronary artery. Six days after occlusion, bipolar pacing catheters were inserted in the right ventricular apex for induction of VT. Testing was repeated in conscious pigs on 6 out of 8 to 19 days after infarction. Monomorphic VT was induced in each animal during each session, using three to four extrastimuli. VT was terminated by burst pacing in 74% of trials; average VT rate was 362 +/- 26 beats/min. VT was prevented in four of eight animals by procainamide and in five of eight animals by magnesium, but was not prevented by lidocaine or metoprolol. The model may be useful in the study of potentially malignant ventricular tachyarrhythmias, important prodromes for sudden death.
Collapse
Affiliation(s)
- D A Kirby
- Department of Nutrition, Harvard School of Public Health
| | | | | | | |
Collapse
|
12
|
Frishman WH, Skolnick AE, Lazar EJ, Fein S. Beta-adrenergic blockade and calcium channel blockade in myocardial infarction. Med Clin North Am 1989; 73:409-36. [PMID: 2563784 DOI: 10.1016/s0025-7125(16)30680-0] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Because of their hemodynamic and antiarrhythmic actions, beta-adrenergic blockers and calcium-entry blockers have been suggested for use in patients with myocardial infarction (MI) for reducing infarct size, preventing ventricular ectopy, and for prolonging life in survivors of acute MI. Experimental studies have suggested their usefulness in these areas. Clinical studies have demonstrated a role for beta-blockers in the hyperacute phase of MI, and in longterm treatment of infarct survivors. Calcium channel blockers appear to have somewhat less utility in patients with Q wave MIs, but may have an important role in therapy of the non-Q wave infarct.
Collapse
Affiliation(s)
- W H Frishman
- Albert Einstein College of Medicine, Bronx, New York
| | | | | | | |
Collapse
|
13
|
Goldman L, Sia ST, Cook EF, Rutherford JD, Weinstein MC. Costs and effectiveness of routine therapy with long-term beta-adrenergic antagonists after acute myocardial infarction. N Engl J Med 1988; 319:152-7. [PMID: 2898733 DOI: 10.1056/nejm198807213190306] [Citation(s) in RCA: 134] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
We analyzed the costs and effectiveness of routine therapy with beta-adrenergic antagonists in patients who survived an acute myocardial infarction. On the basis of data pooled from the literature, this form of therapy resulted in a 25 percent relative reduction annually in the mortality rate for years 1 to 3 and a 7 percent relative reduction for years 4 to 6 after a myocardial infarction. The estimated cost of six years of routine beta-adrenergic-antagonist therapy to save an additional year of life was $23,400 in low-risk patients, $5,900 in medium-risk patients, and $3,600 in high-risk patients, assuming that the entire benefit of earlier treatment is lost immediately after six years. Under a more likely assumption--that the benefit of six years of treatment wears off gradually over the subsequent nine years--the estimated cost of therapy per year of life saved would be $13,000 in low-risk patients, $3,600 in medium-risk patients, and $2,400 in high-risk patients. As compared with coronary-artery bypass grafting and the medical treatment of hypertension, routine beta-adrenergic-antagonist therapy has a relatively favorable cost-effectiveness ratio.
Collapse
Affiliation(s)
- L Goldman
- Division of Clinical Epidemiology, Brigham and Women's Hospital, Boston, MA 02115
| | | | | | | | | |
Collapse
|
14
|
Carney RM, Rich MW, teVelde A, Saini J, Clark K, Freedland KE. The relationship between heart rate, heart rate variability and depression in patients with coronary artery disease. J Psychosom Res 1988; 32:159-64. [PMID: 3404497 DOI: 10.1016/0022-3999(88)90050-5] [Citation(s) in RCA: 153] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
Seventy-seven patients undergoing elective cardiac catheterization were administered a diagnostic psychiatric interview and their mean heart rates and heart rate variability were determined from the results of a 24 hr ambulatory ECG. The mean heart rate for depressed patients with coronary artery disease (CAD) was significantly higher than for nondepressed CAD patients, independent of the patient's age, smoking status, and beta blocker therapy. Heart rate variability was lower in depressed patients but did not achieve significance. With the exception of smoking, which was more common in depressed patients, there were no significant differences between the depressed and nondepressed patients on any other medical or demographic variable assessed. It is concluded that elevated heart rate may represent increased sympathetic tone in depressed CAD patients, and may help to explain the increased morbidity and mortality reported in these patients.
Collapse
Affiliation(s)
- R M Carney
- Department of Psychiatry, Washington University School of Medicine, St. Louis, MO
| | | | | | | | | | | |
Collapse
|
15
|
Goldberg RJ, Gore JM, Alpert JS, Dalen JE. Therapeutic trends in the management of patients with acute myocardial infarction (1975-1984): the Worcester Heart Attack Study. Clin Cardiol 1987; 10:3-8. [PMID: 2880685 DOI: 10.1002/clc.4960100103] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
Abstract
As part of an ongoing community-wide study of time trends in the incidence and case-fatality rates of patients hospitalized with acute myocardial infarction (MI) in all 16 Worcester, Massachusetts, metropolitan hospitals during the years 1975, 1978, 1981, and 1984, changes over time in the therapeutic management of 3263 patients with validated acute myocardial infarction were examined. Beta-blocker (21%, 1975; 52%, 1984) and nitrate (56%, 1975; 93%, 1984) therapy use increased dramatically over time. Use of antiplatelet agents was inconsistent over time, while use of digoxin remained stable, being used in approximately 40% of all patients over the four periods studied. Use of antiarrhythmic medications other than lidocaine decreased consistently over time (31%, 1975; 22%, 1984). Lidocaine use increased between 1975 (31%) and 1978 (52%) and then leveled off to being used in approximately 45% of hospitalized patients with acute MI in 1981 and 1984. A variety of demographic (e.g., age, sex, teaching hospital) and clinical characteristics (e.g., MI order, MI type, MI location, peak CPK findings, occurrence of acute clinical complications) were also associated with the use of these therapies for the combined study periods. The results of this population-based study suggest considerable changes over time in the therapeutic management of patients hospitalized with acute myocardial infarction and of numerous patient demographic and clinical factors associated with their use.
Collapse
|
16
|
Friedman LM, Byington RP, Capone RJ, Furberg CD, Goldstein S, Lichstein E. Effect of propranolol in patients with myocardial infarction and ventricular arrhythmia. J Am Coll Cardiol 1986; 7:1-8. [PMID: 3510232 DOI: 10.1016/s0735-1097(86)80250-9] [Citation(s) in RCA: 93] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
The Beta-Blocker Heart Attack Trial was a placebo-controlled, randomized, double-blind clinical trial of the long-term administration of propranolol hydrochloride to patients who had had at least one myocardial infarction. Among 3,837 patients followed up for an average of 25 months, 3,290 (85.7%) had 24 hour ambulatory electrocardiograms performed at the baseline examination. Four classifications of arrhythmia were examined. One of these, the presence of complex ventricular arrhythmias (at least 10 ventricular premature beats/h, or at least one pair or run of ventricular premature beats or multiform ventricular premature beats) was the subgroup of major interest. Regardless of the classification, the presence of arrhythmia identifies a group of patients with a higher risk of total mortality, coronary heart disease mortality, sudden cardiac death and instantaneous cardiac death. The a priori subgroup hypothesis that sudden death would be preferentially reduced by propranolol in patients with complex ventricular arrhythmias was not supported. The relative benefit of propranolol in reducing sudden death for this subgroup was 28 versus 16% for the subgroup without ventricular arrhythmia (relative risk of 0.72 versus 0.84, a nonsignificant relative difference of 14%). There were similar findings for two of the three other classifications of arrhythmia and for the other response variables. Although propranolol does not appear to be of special relative benefit in patients with ventricular arrhythmia, the presence of the arrhythmia does identify a high-risk group. The mechanism by which propranolol reduces mortality is still unclear, but is probably not solely an antiarrhythmic one.
Collapse
|
17
|
Frishman WH, Ruggio J, Furberg C. Use of beta-adrenergic blocking agents after myocardial infarction. Postgrad Med 1985; 78:40-6, 49-53. [PMID: 2866506 DOI: 10.1080/00325481.1985.11699218] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Long-term clinical trials have been carried out to evaluate the effectiveness of beta-adrenergic blocking agents in modifying the natural history of myocardial infarction (MI). In most of these studies, a lower mortality rate was documented in patients receiving a beta-blocker than in those receiving placebo. The drugs may have both antiarrhythmic and antiischemic effects. In patients without contraindications to beta-blocker treatment, a relative reduction in mortality of 25% can be expected for at least one to two years, with the reduction higher in older patients or patients having complications at infarction. Study results indicate benefit from starting beta-blocker therapy early after infarction, and some benefit from starting late seems a reasonable assumption. Evidence also points to a benefit from prolonged therapy. Beta-blockers are well tolerated in most patients; those major side effects that do occur are often cardiovascular.
Collapse
|
18
|
Byington RP. Beta-blocker heart attack trial: design, methods, and baseline results. Beta-blocker heart attack trial research group. CONTROLLED CLINICAL TRIALS 1984; 5:382-437. [PMID: 6151483 DOI: 10.1016/s0197-2456(84)80017-3] [Citation(s) in RCA: 54] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
The Beta-Blocker Heart Attack Trial (BHAT) was a multicentered, double-blind, randomized, placebo-controlled clinical trial designed to test the efficacy of long-term therapy with propranolol given to survivors of an acute myocardial infarction (MI). Three thousand, eight hundred and thirty-seven men and women, aged 30-69 years, were randomized into either the propranolol or placebo group 5 to 21 days after hospital admission for the MI and were followed at quarterly visits for 12 to 40 months (mean = 25 months). The primary outcome for the trial was all-cause mortality. This article describes the design and baseline findings of the trial. Included is a description of the historical background for the trial and the procedures employed in patient recruitment, randomization, treatment and follow-up. Also included is a comparison between the BHAT population and post-myocardial infarction patients enrolled in the other long-term trials of beta-blockers.
Collapse
|
19
|
Dalen JE, Goldberg RJ, Gore JM, Struckus J. Therapeutic interventions in acute myocardial infarction. Survey of the ACCP Section on Clinical Cardiology. Chest 1984; 86:257-62. [PMID: 6146500 DOI: 10.1378/chest.86.2.257] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023] Open
|
20
|
Abstract
Survivors of the acute phase of a myocardial infarction still have an increased risk of dying, primarily due to causes directly attributable to their coronary heart disease. This review of randomized clinical trials of various interventions with the potential to prolong life in these patients is an attempt to answer a vitally important question. What, if anything, can be done to improve the long-term prognosis in patients who have survived the initial one or two weeks after suffering an acute myocardial infarction? Seven classes of intervention are considered: anticoagulants, platelet-active drugs, lipid-lowering regimens, antiarrhythmic agents, physical exercise, calcium antagonists and beta-blockers. So far only beta-blockers have been shown to have a favorable effect on long-term survival. Many of the trials reviewed had design limitations; in particular, the sample size was often too small for the results to be conclusive.
Collapse
|
21
|
Frishman WH, Furberg CD, Friedewald WT. The use of beta-adrenergic blocking drugs in patients with myocardial infarction. Curr Probl Cardiol 1984; 9:1-50. [PMID: 6146495 DOI: 10.1016/0146-2806(84)90015-x] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
|
22
|
|
23
|
Abstract
Oxprenolol is a potent noncardioselective beta-adrenoceptor blocking drug with partial agonist activity of proved efficacy and high tolerability in patients at risk of various cardiovascular disease syndromes. The drug rapidly relieves angina and attenuates the electrocardiographic evidence of myocardial ischemia. It is a potent antihypertensive drug that not only reduces the blood pressure at rest but also prevents the surges associated with exercise and psychic stress. Oxprenolol has substantial benefit in the alleviation of many of the somatic sequelae of psychic stress and anxiety. The drug also suppresses the cardiovascular and metabolic effects of cigarette smoking. In the field of primary prevention, oxprenolol has attributes that could be expected to reduce the long-term cardiovascular complications of high blood pressure. In the secondary prevention, it reduces the further incidence of sudden death in patients in whom administration is started in relatively small doses within a few weeks after acute myocardial infarction. In the 15 years that the drug has been available for clinical prescription, it has established a reputation for high clinical tolerability.
Collapse
|
24
|
Abstract
This report is a review of greater than 18 years of experience with clinical trials that have examined the effect of beta blockers on mortality after acute myocardial infarction (MI). Despite inadequate sample size, a substantial number of the early randomized trials demonstrated a trend toward reduction in mortality after MI using a number of beta blockers. This review highlights the larger prospective randomized trials, especially the Multicenter International Trial of practolol, the Norwegian Multicenter Study of timolol and the Beta-Blocker Heart Attack Trial (BHAT) of propranolol. The combined strength of these long-term trials, comprising greater than 8,000 patients, demonstrates a consistent and statistically significant reduction in mortality after MI. Both the Norwegian timolol study and BHAT further document a substantial reduction in mortality in patients stratified according to risk groups, with a reduction in mortality after complicated or uncomplicated first MI or in patients with prior MI. These 2 studies also document a reduction in sudden death mortality in the first year after MI. Data regarding subendocardial MI is more variable, but the Norwegian timolol study documents a substantial reduction in mortality after subendocardial MI. Based on this review, we recommend treatment of all patients who can tolerate beta blockade after acute MI, beginning in the late hospitalization phase and continuing for at least 2 years.
Collapse
|
25
|
Goldman GJ, Pichard AD. The natural history of coronary artery disease: does medical therapy improve the prognosis? Prog Cardiovasc Dis 1983; 25:513-52. [PMID: 6133314 DOI: 10.1016/0033-0620(83)90022-1] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
|
26
|
Puddu PE, Pasternac A, Tubau JF, Król R, Farley L, de Champlain J. QT interval prolongation and increased plasma catecholamine levels in patients with mitral valve prolapse. Am Heart J 1983; 105:422-8. [PMID: 6131602 DOI: 10.1016/0002-8703(83)90359-9] [Citation(s) in RCA: 66] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
The heart rate corrected QT interval (QTc) and plasma catecholamine (CA) and norepinephrine (NE) levels were measured in 15 symptomatic patients with idiopathic mitral valve prolapse (MVP) and in 19 control subjects. MVP patients showed longer mean QTc and were divided into two groups: group A normal QTc (greater than 440 msec) and group B prolonged QTc (less than 440 msec). In supine resting conditions CA levels were as follows: group A 0.420 +/- 0.035 ng/ml and group B 0.619 +/- 0.104 ng/ml (p less than 0.05); both were greater than control values (0.348 +/- 0.017 ng/ml, p less than 0.005). NE levels were as follows: group A 0.350 +/- 0.031 ng/ml and group B 0.376 +/- 0.052 ng/ml (NS); both were greater than control values (0.242 +/- 0.025 ng/ml, (p less than 0.05). When a standing position was assumed, CA and NE levels increased significantly in all groups but this was most marked in group B as compared to control levels (CA: 1.039 +/- 0.123 ng/ml versus 0.625 +/- 0.037 ng/ml; NE: 0.737 +/- 0.076 ng/ml versus 0.504 +/- 0.031 ng/ml) (p less than 0.001 and p less than 0.05, respectively). Thus the longest QTc was observed in patients with MVP who had the highest levels of CA and NE, in both supine and standing positions. These data may account, in part, for the occurrence of severe ventricular arrhythmias in some patients with MVP and may offer a rationale for adrenergic blockade in that subset of patients with MVP and markedly prolonged QTc.
Collapse
|
27
|
Graboys TB, Lown B, Podrid PJ, DeSilva R. Long-term survival of patients with malignant ventricular arrhythmia treated with antiarrhythmic drugs. Am J Cardiol 1982; 50:437-43. [PMID: 6180622 DOI: 10.1016/0002-9149(82)90307-1] [Citation(s) in RCA: 430] [Impact Index Per Article: 10.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
The protective effect of antiarrhythmic agents for patients with malignant ventricular arrhythmia (defined as noninfarction ventricular fibrillation or sustained hemodynamically compromising ventricular tachycardia) remains uncertain. We have analyzed survival among 123 such patients (98 males, 25 females, average age 53.6 years) dependent on the abolition of antiarrhythmic drugs of salvos of ventricular tachycardia and R-on-T ventricular premature beats (Lown grades 4B and 5). Over an average follow-up of 29.6 months there were 35 deaths (11.2 percent annual mortality rate) of whom 23 patients succumbed suddenly (8.2 percent annual mortality rate). Among 98 patients in whom antiarrhythmic drugs abolished grades 4B and 5 ventricular premature beats, only 6 sudden deaths occurred for a 2.3 percent annual mortality rate. Of the 25 patients in whom advanced ventricular premature beats were not controlled, 17 died suddenly. Seventy-nine patients had left ventricular studies suitable for analysis. Among 44 patients with left ventricular dysfunction, control of ventricular premature beats was a critical element predicting survival. The annual sudden death rate for the 12 noncontrolled patients with left ventricular dysfunction was 41 percent contrasting with only 3.1 percent for the 32 patients with similar abnormalities in ventricular function in whom advanced ventricular premature beats were abolished. It is concluded that antiarrhythmic drugs can protect against the recurrence of life-threatening arrhythmias in patients who have manifest ventricular fibrillation or ventricular tachycardia and that abolition of certain advanced grades of ventricular premature beats provides an effective therapeutic objective.
Collapse
|
28
|
Burley DM. Therapeutic progress--Review III. Can drugs prevent recurrent myocardial infarction? JOURNAL OF CLINICAL AND HOSPITAL PHARMACY 1982; 7:1-15. [PMID: 6124554 DOI: 10.1111/j.1365-2710.1982.tb00902.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
|
29
|
Hansteen V, Møinichen E, Lorentsen E, Andersen A, Strøm O, Søiland K, Dyrbekk D, Refsum AM, Tromsdal A, Knudsen K, Eika C, Bakken J, Smith P, Hoff PI. One year's treatment with propranolol after myocardial infarction: preliminary report of Norwegian multicentre trial. BMJ : BRITISH MEDICAL JOURNAL 1982; 284:155-60. [PMID: 6799077 PMCID: PMC1495539 DOI: 10.1136/bmj.284.6310.155] [Citation(s) in RCA: 169] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
A prospective, randomised, double-blind study was performed to compare the effects of propranolol and placebo on sudden cardiac death in a high-risk group of patients who survived acute myocardial infarction. Altogether 4929 patients with definite acute myocardial infarction were screened for inclusion: 574 (11.6%) died before randomisation, and 3795 (77%) were excluded. Five hundred and sixty patients aged 35 to 70 years were stratified into two risk groups and randomly assigned treatment with propranolol 40 mg four times a day or placebo. Treatment started four to six days after the infarction. By one year there had been 11 sudden deaths in the propranolol group and 23 in the placebo group (p less than 0.038, two-tailed test analysed according to the "intention-to-treat" principle). Altogether there were 25 deaths in the propranolol group and 37 in the placebo group (P less than 0.12), with 16 and 21 non-fatal reinfarctions respectively. A quarter of the patients were withdrawn from each group. Withdrawal because of heart failure during the first two weeks of treatment was significantly more common among propranolol-treated patients than among the controls, but thereafter the withdrawal rate was the same. The significant reduction in sudden death was comparable with that after alprenolol, practolol, and timolol, which suggests that the mechanism of prevention is beta-blockade rather than any other pharmacological property of the individual drugs.
Collapse
|
30
|
|
31
|
May GS, Eberlein KA, Furberg CD, Passamani ER, DeMets DL. Secondary prevention after myocardial infarction: a review of long-term trials. Prog Cardiovasc Dis 1982; 24:331-52. [PMID: 6119737 DOI: 10.1016/0033-0620(82)90010-x] [Citation(s) in RCA: 262] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
|
32
|
|
33
|
Abstract
The Beta Blocker Heart Attack Trial (BHAT) is a multicenter, randomized, double-blind, placebo control clinical trial sponsored by the National Heart, Lung, and Blood Institute designed to test the effectiveness of regular propranolol administration in reducing total mortality in patients who have survived a recent acute myocardial infarction. A number of other fatal and nonfatal response variables are also being monitored. Three thousand eight hundred thirty-seven patients, ages 30-69, are being followed at 31 clinical centers for a minimum of about 2 and a maximum of 4 years after the infarction. A number of design features of BHAT are discussed. These include maintenance of patient logs, guidelines for obtaining informed consent of patients, assessment of patient knowledge about BHAT, adjustment of study drug dose based on serum levels, and comparison of 1-hr and 24-hr ambulatory electrocardiogram readings.
Collapse
|
34
|
Abstract
Since 1968, there has been a dramatic, unprecedented decline in mortality from cardiovascular disease in the United States, especially from coronary heart disease and stroke. The decline has now been confirmed as real and has been observed in all age, sex, and race groups. Possible causes of the decline in coronary heart disease mortality include the development of the concept of acute coronary care, new drugs, sophisticated surgical techniques such as coronary artery bypass, noninvasive diagnostic methods for earlier disease detection, and the identification of specific cardiovascular risk factors. The decline has been temporally related to risk factor awareness and modification (cigarette smoking cessation, hypertension control, diet change and reduction in cholesterol). Thus, both primary prevention through lifestyle changes and improved treatment regimes have played a role in the decline.
Collapse
|
35
|
|
36
|
Secondary prevention in survivors of myocardial infarction. Joint Recommendations by the International Society and Federation of Cardiology, Scientific Councils on Arteriosclerosis, Epidemiology and Prevention, and Rehabilitation. BMJ : BRITISH MEDICAL JOURNAL 1981; 282:894-6. [PMID: 6111375 PMCID: PMC1504709 DOI: 10.1136/bmj.282.6267.894] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
|
37
|
|
38
|
Baber NS. Clinical experience with beta adrenergic blocking agents in myocardial ischaemia: a dilemma and a challenge. Pharmacol Ther 1981; 13:285-320. [PMID: 6116243 DOI: 10.1016/0163-7258(81)90004-8] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
|
39
|
|
40
|
|
41
|
|
42
|
Aellig WH. Activity and duration of action of pindolol and alprenolol compared in healthy volunteers. Eur J Clin Pharmacol 1978; 14:305-8. [PMID: 729623 DOI: 10.1007/bf00611898] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
An improvement in the prognosis of myocardial infarction has been reported after long term treatment with alprenolol 200 mg twice daily. Therefore, an experiment was carried out to find the dose of pindolol given once daily which would show cardiac beta-adrenoceptor blockade at least equipotent to that obtained during treatment with alprenolol 200 mg twice daily. Cardiac beta-adrenoceptor blocking activity and its time course during treatment with pindolol (15 mg and 20 mg given once daily) and alprenolol (200 mg given 12-hourly) for three days were compared in 6 healthy volunteers. The reduction in exercise-induced tachycardia as a measure of cariac beta-adrenoceptor blockade was significantly greater after pindolol 15 mg and 20 mg than after alprenolol 200 mg. On the morning of the fourth day, i.e. 24 h after the last dose of pindolol and only 12 h after the last dose of alprenolol, the effects of pindolol at both dose levels were slightly greater than those of alprenolol. This difference was not statistically significant. It can be concluded that pindolol 15 mg once daily produces a cardiac beta-adrenoceptor blockade at least equipotent to that of alprenolol 200 mg given 12-hourly.
Collapse
|
43
|
Rabinowitz SH, Lown B. Central neurochemical factors related to serotonin metabolism and cardiac ventricular vulnerability for repetitive electrical activity. Am J Cardiol 1978; 41:516-22. [PMID: 75687 DOI: 10.1016/0002-9149(78)90009-7] [Citation(s) in RCA: 33] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Sympathetic neural activity modifies cardiac excitability and lowers the threshold of the vulnerable period for ventricular fibrillation. Sympathetic neural traffic to the heart can be diminished by administering serotonin precursors that localize in the central nervous system. In this study anesthetized dogs were injected with either of the serotonin precursors L-tryptophan or 5-hydroxy-L-tryptophan in conjunction with the monoamine oxidase inhibitor pheneizine and the selective peripheral L-amino acid decarboxylase inhibitor carbidopa. Ventricular vulnerability was evaluated by measuring the repetitive extrasystole threshold. A sustained increase of 50 percent in this threshold resulted only with use of biochemical measures that presumably increase serotonin levels in the central nervous system. Thus neuropharmacologic measures affecting central sympathetic activity alter cardiac vulnerability and may protect against ventricular fibrillation.
Collapse
|
44
|
Schroeder JS. Newer antiarrhythmic agents for patients with coronary artery disease. Angiology 1978; 29:22-32. [PMID: 343649 DOI: 10.1177/000331977802900104] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
|
45
|
Abstract
Brain stimulation can provoke a variety of arrhythmias and lower the ventricular vulnerable threshold. In the animal with acute myocardial ischemia such stimuli suffice to provoke ventricular fibrillation. Vagal neural traffic or adrenal catecholamines are not the conduits for this brain-heart linkage. Accompanying increases in heart rate or blood pressure are not prerequisites for the changes in cardiac excitability. Increased sympathetic activity, whether induced by neural or neurohumoral action, predisposes the heart to ventricular fibrillation. Protection can be achieved with surgical and pharmacologic denervation or reflex reduction in sympathetic tone. With acute myocardial ischemia, augmented sympathetic activity accounts for the early surge of ectopic activity frequently precipitating ventricular fibrillation. Asymmetries in sympathetic neural discharge may also contribute to the genesis of serious arrhythmias. The vagus nerve, through its muscarinic action, exerts an indirect effect on cardiac vulnerability, the consequence of annulment of concomitant adrenergic influence, rather than of any direct cholinergic action on the ventricles. There exist anatomic, physiologic as well as molecular bases for such interactions. Available experimental evidence indicates that environmental stresses of diverse types can injure the heart, lower the threshold of cardiac vulnerability to ventricular fibrillation and, in the animal with coronary occlusion, provoke potentially malignant ventricular arrhythmias. Available evidence indicates that in man, as in the experimental animal, administration of catecholamines can induce ventricular arrhythmia, whereas vagal activity exerts an opposite effect. Furthermore, in certain subjects diverse stresses and various psychologic states provoke ventricular ectopic activity.
Collapse
|
46
|
Comerford MB, Besterman EM. Some observations of the long-term clinical response to selective beta-blockade (metoprolol) in angina pectoris. Scott Med J 1977; 22:80-2. [PMID: 836575 DOI: 10.1177/003693307702200121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|